- Type II DM:
- HbA1c <8% or treatment-naïve:
- Initially PO 0.5mg 15-30min before each meal
- Maintenance: PO 0.5-4mg
- May double preprandial dose no more frequently than once weekly
- Max: 4mg/dose up to 16mg/day
- HbA1c <8% or treatment-naïve:
-
- HbA1c >8% or treatment-experienced:
- Initially 1-2mg every 15-30min before each meal
- Maintenance: PO 0.5-4mg
- May double preprandial dose no more frequently than once weekly
- Max: 4mg/dose up to 16mg/day
- HbA1c >8% or treatment-experienced:
- Tablet:
- 0.5mg
- 1mg
- 2mg
- Dose taken 15-30 minutes before meal
- In case of skipped meals, skip the scheduled repaglinide dose to reduce the risk of hypoglycemia
Meglitinide antidiabetics
It stimulates pancreatic islet beta cell insulin release, lowering serum glucose levels
- Hypoglycemia
- URI symptoms
- Headache
- Arthralgia
- Diarrhea
- Back pain
- Nausea
- Vomiting
- Constipation
- Dyspepsia
- Paresthesia
- Chest pain
- UTI
- Tooth disorder
- Hypersensitivity to class/components
- Diabetic ketoacidosis
- Type I DM
- Gemfibrozil
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Contraindicated |
Schedule | Not controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Novonorm | 0.5mg | Tablet | 30’s | Novo Nordisk | Phillips Therapeutics |
Novonorm | 1mg | Tablet | 30’s | Novo Nordisk | Phillips Therapeutics |
Novonorm | 2mg | Tablet | 30’s | Novo Nordisk | Phillips Therapeutics |